| June 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
NVO |
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia |
Trial Milestone |
Phase 1 |
| June 1, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
MRNA |
Intismeran + KEYTRUDA — 5-Year Phase 2b Melanoma Data |
Conference |
Phase 2b |
| June 1, 2026 |
ARWR |
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia |
Trial Milestone |
Phase 3 |
| June 1, 2026 |
PRAX |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
IDYA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 1, 2026 |
EIKN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 1, 2026 |
MLTX |
8-K filed: Material agreement |
Corporate |
— |
| June 1, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
ORKA |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
EWTX |
A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults |
Trial Milestone |
Phase 1 |
| June 1, 2026 |
EWTX |
8-K filed: Material agreement |
Corporate |
— |
| June 1, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
OTLC |
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer |
Trial Milestone |
Phase 2/Phase 3 |
| June 1, 2026 |
IMRX |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
SYRE |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 1, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 1, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| June 1, 2026 |
TCRX |
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA) |
Trial Milestone |
Phase 1 |
| June 1, 2026 |
WST |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| June 2, 2026 |
LLY |
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities |
Trial Milestone |
Phase 3 |
| June 2, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 2, 2026 |
URGN |
8-K filed: Other event |
Filing |
— |
| June 2, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| June 2, 2026 |
TVTX |
8-K filed: Material agreement |
Corporate |
— |
| June 2, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 2, 2026 |
VERA |
8-K filed: Other event |
Filing |
— |
| June 2, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 2, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| June 2, 2026 |
SLS |
8-K filed: Other event |
Filing |
— |
| June 2, 2026 |
ONCY |
8-K filed: Leadership change, Other event |
Corporate |
— |
| June 2, 2026 |
BTMD |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| June 2, 2026 |
TPST |
8-K filed: Material agreement |
Corporate |
— |
| June 2, 2026 |
ACHV |
8-K filed: Leadership change |
Corporate |
— |
| June 2, 2026 |
GOSS |
8-K filed: Other event |
Filing |
— |
| June 2, 2026 |
MNKD |
8-K filed: Other event |
Filing |
— |
| June 2, 2026 |
LTRN |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 2, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| June 3, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 3, 2026 |
AXSM |
8-K filed: Other event |
Filing |
— |
| June 3, 2026 |
XENE |
8-K filed: Leadership change |
Corporate |
— |
| June 3, 2026 |
SMMT |
8-K filed: Other event |
Filing |
— |
| June 3, 2026 |
TGTX |
8-K filed: Other event |
Filing |
— |
| June 3, 2026 |
IDYA |
8-K filed: Other event |
Filing |
— |
| June 3, 2026 |
OCGN |
8-K filed: Leadership change |
Corporate |
— |
| June 3, 2026 |
CABA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 3, 2026 |
RGNX |
8-K filed: Other event |
Filing |
— |
| June 3, 2026 |
CORT |
8-K filed: Other event |
Filing |
— |
| June 3, 2026 |
DYN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 3, 2026 |
AVLN |
Quarterly results filed (8-K) |
Earnings |
— |
| June 3, 2026 |
BCTX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 3, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 3, 2026 |
SGMT |
8-K filed: Leadership change |
Corporate |
— |
| June 3, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 3, 2026 |
MLYS |
8-K filed: Other event |
Filing |
— |
| June 3, 2026 |
MLYS |
8-K filed: Material agreement |
Corporate |
— |
| June 3, 2026 |
CERS |
8-K filed: Leadership change |
Corporate |
— |
| June 3, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| June 3, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| June 4, 2026 |
BMRN |
8-K filed: Leadership change |
Corporate |
— |
| June 4, 2026 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 4, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| June 4, 2026 |
SRPT |
8-K filed: Leadership change |
Corporate |
— |
| June 4, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| June 4, 2026 |
SNDX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 4, 2026 |
IMNN |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| June 4, 2026 |
KURA |
8-K filed: Leadership change |
Corporate |
— |
| June 4, 2026 |
ABEO |
8-K filed: Other event |
Filing |
— |
| June 4, 2026 |
CRSP |
8-K filed: Leadership change |
Corporate |
— |
| June 4, 2026 |
MPLT |
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia |
Trial Milestone |
Phase 2 |
| June 4, 2026 |
TPST |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| June 4, 2026 |
LPCN |
8-K filed: Leadership change |
Corporate |
— |
| June 4, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| June 4, 2026 |
BYSI |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| June 4, 2026 |
FATE |
8-K filed: Other event |
Filing |
— |
| June 5, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 5, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 5, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| June 5, 2026 |
SVA |
Results filed (20-F) |
Earnings |
— |
| June 5, 2026 |
HUMA |
8-K filed: Other event |
Filing |
— |
| June 5, 2026 |
NVCR |
8-K filed: Leadership change |
Corporate |
— |
| June 5, 2026 |
GRCE |
8-K filed: Leadership change |
Corporate |
— |
| June 5, 2026 |
MBX |
8-K filed: Leadership change |
Corporate |
— |
| June 5, 2026 |
CLYM |
8-K filed: Other event |
Filing |
— |
| June 5, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 5, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| June 5, 2026 |
GOSS |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| June 5, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 5, 2026 |
CNSY |
8-K filed: Material agreement |
Corporate |
— |
| June 8, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 8, 2026 |
SNY |
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) |
Trial Milestone |
Phase 3 |
| June 8, 2026 |
SNY |
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) |
Trial Milestone |
Phase 3 |
| June 8, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| June 8, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| June 8, 2026 |
INCY |
8-K filed: Other event |
Filing |
— |
| June 8, 2026 |
ONC |
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies |
Trial Milestone |
Phase 1 |
| June 8, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 8, 2026 |
IONS |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| June 8, 2026 |
LQDA |
8-K filed: Other event |
Filing |
— |
| June 8, 2026 |
SVRA |
8-K filed: Leadership change |
Corporate |
— |
| June 8, 2026 |
VOR |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 8, 2026 |
NRIX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| June 8, 2026 |
TNGX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 8, 2026 |
NGNE |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 8, 2026 |
CLYM |
8-K filed: Leadership change |
Corporate |
— |
| June 8, 2026 |
KYMR |
8-K filed: Leadership change |
Corporate |
— |
| June 8, 2026 |
CRMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 8, 2026 |
CERS |
8-K filed: Material agreement |
Corporate |
— |
| June 8, 2026 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 9, 2026 |
NVS |
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria |
Trial Milestone |
Phase 2 |
| June 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| June 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| June 9, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 9, 2026 |
AXSM |
8-K filed: Leadership change |
Corporate |
— |
| June 9, 2026 |
VRCA |
8-K filed: Leadership change |
Corporate |
— |
| June 9, 2026 |
MLTX |
8-K filed: Leadership change |
Corporate |
— |
| June 9, 2026 |
VTGN |
8-K filed: Other event |
Filing |
— |
| June 9, 2026 |
RNAC |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 9, 2026 |
AWHL |
8-K filed: Material agreement |
Corporate |
— |
| June 9, 2026 |
KYNB |
8-K filed: Other event |
Filing |
— |
| June 9, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| June 9, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| June 9, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 10, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| June 10, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| June 10, 2026 |
IDYA |
8-K filed: Other event |
Filing |
— |
| June 10, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| June 10, 2026 |
EIKN |
8-K filed: Leadership change |
Corporate |
— |
| June 10, 2026 |
IOVA |
8-K filed: Other event |
Filing |
— |
| June 10, 2026 |
VIR |
8-K filed: Leadership change |
Corporate |
— |
| June 10, 2026 |
HUMA |
8-K filed: Other event |
Filing |
— |
| June 10, 2026 |
LBRX |
8-K filed: Leadership change |
Corporate |
— |
| June 10, 2026 |
SNDX |
8-K filed: Material agreement |
Corporate |
— |
| June 10, 2026 |
SNDX |
8-K filed: Leadership change |
Corporate |
— |
| June 10, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| June 10, 2026 |
TNGX |
8-K filed: Material agreement |
Corporate |
— |
| June 10, 2026 |
ABEO |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 10, 2026 |
ALDX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| June 10, 2026 |
TRDA |
8-K filed: Leadership change |
Corporate |
— |
| June 10, 2026 |
FTH |
8-K filed: Leadership change |
Corporate |
— |
| June 10, 2026 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 11, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| June 11, 2026 |
ABBV |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| June 11, 2026 |
ONC |
8-K filed: Leadership change |
Corporate |
— |
| June 11, 2026 |
SMMT |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 11, 2026 |
OCGN |
8-K filed: Other event |
Filing |
— |
| June 11, 2026 |
HUMA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| June 11, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 11, 2026 |
NRIX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 11, 2026 |
PCRX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| June 11, 2026 |
CLYM |
8-K filed: Other event |
Filing |
— |
| June 11, 2026 |
OGN |
8-K filed: Leadership change |
Corporate |
— |
| June 11, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| June 11, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| June 11, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 11, 2026 |
KPRX |
8-K filed: Leadership change |
Corporate |
— |
| June 12, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 12, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| June 12, 2026 |
IONS |
8-K filed: Other event |
Filing |
— |
| June 12, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| June 12, 2026 |
ARWR |
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia |
Trial Milestone |
Phase 3 |
| June 12, 2026 |
DFTX |
8-K filed: Leadership change |
Corporate |
— |
| June 12, 2026 |
OCUL |
8-K filed: Leadership change |
Corporate |
— |
| June 12, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| June 12, 2026 |
DNTH |
8-K filed: Other event |
Filing |
— |
| June 12, 2026 |
MBX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 12, 2026 |
CLYM |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 12, 2026 |
TRAW |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 12, 2026 |
ABEO |
8-K filed: Leadership change |
Corporate |
— |
| June 12, 2026 |
NTHI |
8-K filed: Material agreement |
Corporate |
— |
| June 12, 2026 |
SGMT |
8-K filed: Leadership change |
Corporate |
— |
| June 12, 2026 |
BCRX |
8-K filed: Leadership change |
Corporate |
— |
| June 12, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| June 12, 2026 |
GNPX |
8-K filed: Listing / standard notice, Other event |
Corporate |
— |
| June 13, 2026 |
MRK |
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) |
Trial Milestone |
Phase 1 |
| June 15, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
SVA |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
RVMD |
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) |
Trial Milestone |
Phase 3 |
| June 15, 2026 |
BMRN |
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature |
Trial Milestone |
Phase 2 |
| June 15, 2026 |
ALKS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 15, 2026 |
FDMT |
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2026 |
FDMT |
4D-310 in Adults With Fabry Disease and Cardiac Involvement |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2026 |
VSTM |
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2026 |
VSTM |
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
NTLA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 15, 2026 |
VTRS |
8-K filed: Other event |
Filing |
— |
| June 15, 2026 |
RYTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 15, 2026 |
VTGN |
Quarterly results filed (8-K) |
Earnings |
— |
| June 15, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
QURE |
8-K filed: Leadership change |
Corporate |
— |
| June 15, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| June 15, 2026 |
IMRX |
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2026 |
IMRX |
8-K filed: Leadership change |
Corporate |
— |
| June 15, 2026 |
LXEO |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 15, 2026 |
SYRE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 15, 2026 |
IMNM |
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants |
Trial Milestone |
Phase 1 |
| June 15, 2026 |
ACTU |
9-ING-41 in Patients With Advanced Cancers |
Trial Milestone |
Phase 2 |
| June 15, 2026 |
FATE |
8-K filed: Leadership change |
Corporate |
— |
| June 15, 2026 |
FTH |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| June 15, 2026 |
QTTB |
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) |
Trial Milestone |
Phase 2 |
| June 16, 2026 |
REGN |
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation |
Trial Milestone |
Phase 2 |
| June 16, 2026 |
EXEL |
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer |
Trial Milestone |
Phase 3 |
| June 16, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 16, 2026 |
MRNA |
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations |
Trial Milestone |
Phase 4 |
| June 16, 2026 |
ARWR |
8-K filed: Leadership change |
Corporate |
— |
| June 16, 2026 |
CADL |
8-K filed: Leadership change |
Corporate |
— |
| June 16, 2026 |
TVTX |
8-K filed: Leadership change |
Corporate |
— |
| June 16, 2026 |
PVLA |
8-K filed: Leadership change |
Corporate |
— |
| June 16, 2026 |
IRD |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 16, 2026 |
IRD |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 16, 2026 |
IMNN |
8-K filed: Leadership change |
Corporate |
— |
| June 16, 2026 |
PBH |
8-K filed: Material agreement, Acquisition completed, Other event |
Corporate |
— |
| June 16, 2026 |
ALT |
8-K filed: Other event |
Filing |
— |
| June 16, 2026 |
KYTX |
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis |
Trial Milestone |
Phase 1/Phase 2 |
| June 16, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| June 16, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| June 16, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| June 16, 2026 |
CGEM |
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| June 16, 2026 |
ILMN |
Daniel Skovronsky (Lilly CSO) Joins Board |
Corporate |
— |
| June 17, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| June 17, 2026 |
REGN |
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies |
Trial Milestone |
Phase 2 |
| June 17, 2026 |
TAK |
Results filed (20-F) |
Earnings |
— |
| June 17, 2026 |
IONS |
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) |
Trial Milestone |
Phase 3 |
| June 17, 2026 |
ARWR |
Study of Plozasiran in Adults With Severe Hypertriglyceridemia |
Trial Milestone |
Phase 3 |
| June 17, 2026 |
VSTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 17, 2026 |
MDGL |
8-K filed: Leadership change |
Corporate |
— |
| June 17, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| June 17, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| June 17, 2026 |
CORT |
8-K filed: Other event |
Filing |
— |
| June 17, 2026 |
DYN |
8-K filed: Material agreement |
Corporate |
— |
| June 17, 2026 |
VTGN |
8-K filed: Leadership change |
Corporate |
— |
| June 17, 2026 |
QURE |
8-K filed: Other event |
Filing |
— |
| June 17, 2026 |
AVLN |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 17, 2026 |
ARDX |
8-K filed: Leadership change |
Corporate |
— |
| June 17, 2026 |
BTMD |
8-K/A filed: Leadership change |
Corporate |
— |
| June 17, 2026 |
GOSS |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 17, 2026 |
MNKD |
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis |
Trial Milestone |
Phase 1 |
| June 17, 2026 |
ACRV |
8-K filed: Leadership change |
Corporate |
— |
| June 17, 2026 |
RIGL |
8-K filed: Acquisition completed |
Corporate |
— |
| June 18, 2026 |
PFE |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 18, 2026 |
PFE |
8-K filed: Leadership change |
Corporate |
— |
| June 18, 2026 |
AGIO |
8-K filed: Leadership change |
Corporate |
— |
| June 18, 2026 |
MRNA |
mFLUSIVA (mRNA-1010) — FDA Advisory Committee Vote |
Regulatory |
BLA review |
| June 18, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 18, 2026 |
VTRS |
8-K filed: Material agreement |
Corporate |
— |
| June 18, 2026 |
DNLI |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| June 18, 2026 |
ATNM |
8-K filed: Other event |
Filing |
— |
| June 18, 2026 |
PTGX |
8-K filed: Leadership change |
Corporate |
— |
| June 18, 2026 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 18, 2026 |
GRCE |
8-K filed: Other event |
Filing |
— |
| June 18, 2026 |
GRCE |
Quarterly results filed (8-K) |
Earnings |
— |
| June 18, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 18, 2026 |
OMER |
8-K filed: Other event |
Filing |
— |
| June 18, 2026 |
PVCT |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 18, 2026 |
MPLT |
8-K filed: Leadership change |
Corporate |
— |
| June 18, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 18, 2026 |
KPRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 18, 2026 |
FTH |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 18, 2026 |
GNPX |
8-K filed: Leadership change |
Corporate |
— |
| June 22, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 22, 2026 |
ABBV |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 22, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| June 22, 2026 |
INCY |
8-K filed: Other event |
Filing |
— |
| June 22, 2026 |
BIIB |
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa |
Trial Milestone |
Phase 3 |
| June 22, 2026 |
RVMD |
8-K filed: Leadership change |
Corporate |
— |
| June 22, 2026 |
PRAX |
8-K filed: Other event |
Filing |
— |
| June 22, 2026 |
TSHA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 22, 2026 |
DFTX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 22, 2026 |
EYPT |
8-K filed: Leadership change |
Corporate |
— |
| June 22, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 22, 2026 |
MLTX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 22, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| June 22, 2026 |
DYN |
8-K filed: Leadership change |
Corporate |
— |
| June 22, 2026 |
AWHL |
8-K filed: Leadership change |
Corporate |
— |
| June 22, 2026 |
QURE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 22, 2026 |
ORIC |
8-K filed: Leadership change |
Corporate |
— |
| June 22, 2026 |
CLRB |
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom |
Trial Milestone |
Phase 2 |
| June 22, 2026 |
TRAW |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 22, 2026 |
MPLT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 22, 2026 |
TCRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 22, 2026 |
ALLO |
8-K filed: Other event |
Filing |
— |
| June 22, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| June 23, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| June 23, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 23, 2026 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 23, 2026 |
VSTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 23, 2026 |
IDYA |
8-K filed: Other event |
Filing |
— |
| June 23, 2026 |
PCVX |
8-K filed: Leadership change |
Corporate |
— |
| June 23, 2026 |
URGN |
8-K filed: Leadership change |
Corporate |
— |
| June 23, 2026 |
ALMS |
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus |
Trial Milestone |
Phase 2 |
| June 23, 2026 |
TNGX |
8-K filed: Leadership change |
Corporate |
— |
| June 23, 2026 |
PHAT |
8-K filed: Other event |
Filing |
— |
| June 23, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 23, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| June 23, 2026 |
ILMN |
8-K filed: Leadership change |
Corporate |
— |
| June 24, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| June 24, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 24, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| June 24, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 24, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 24, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 24, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| June 24, 2026 |
BIIB |
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old |
Trial Milestone |
Phase 1 |
| June 24, 2026 |
IONS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 24, 2026 |
DFTX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 24, 2026 |
RYTM |
Open-Label Extension Study of Setmelanotide |
Trial Milestone |
Phase 3 |
| June 24, 2026 |
QURE |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 24, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| June 24, 2026 |
PGEN |
8-K filed: Leadership change |
Corporate |
— |
| June 24, 2026 |
APLM |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
JNJ |
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder |
Trial Milestone |
Phase 2 |
| June 25, 2026 |
ABBV |
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants |
Trial Milestone |
Phase 1 |
| June 25, 2026 |
TSHA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 25, 2026 |
MLTX |
8-K filed: Material agreement |
Corporate |
— |
| June 25, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
SLS |
8-K filed: Leadership change |
Corporate |
— |
| June 25, 2026 |
KYTX |
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome |
Trial Milestone |
Phase 2 |
| June 25, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
KYMR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 25, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 25, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 26, 2026 |
AZN |
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma |
Trial Milestone |
Phase 1 |
| June 26, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 26, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 26, 2026 |
ONC |
8-K filed: Other event |
Filing |
— |
| June 26, 2026 |
CLDX |
8-K filed: Leadership change |
Corporate |
— |
| June 26, 2026 |
REPL |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 26, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| June 26, 2026 |
ALXO |
8-K filed: Material agreement |
Corporate |
— |
| June 26, 2026 |
PHVS |
6-K filed: Foreign issuer report |
Filing |
— |
| June 26, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| June 26, 2026 |
CAPR |
8-K filed: Other event |
Filing |
— |
| June 26, 2026 |
BCTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 26, 2026 |
OTLK |
8-K filed: Listing / standard notice |
Corporate |
— |
| June 26, 2026 |
CLLS |
6-K/A filed: Foreign issuer report |
Filing |
— |
| June 27, 2026 |
WVE |
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) |
Trial Milestone |
Phase 1/Phase 2 |
| June 29, 2026 |
AZN |
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels |
Trial Milestone |
Phase 1 |
| June 29, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| June 29, 2026 |
AZN |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| June 29, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 29, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 29, 2026 |
TAK |
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults |
Trial Milestone |
Phase 3 |
| June 29, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| June 29, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| June 29, 2026 |
PRAX |
8-K filed: Other event |
Filing |
— |
| June 29, 2026 |
FDMT |
8-K filed: Material agreement |
Corporate |
— |
| June 29, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| June 29, 2026 |
REPL |
Quarterly results filed (8-K) |
Earnings |
— |
| June 29, 2026 |
RGNX |
8-K filed: Other event |
Filing |
— |
| June 29, 2026 |
TARA |
8-K filed: Leadership change |
Corporate |
— |
| June 29, 2026 |
IMUX |
8-K filed: Leadership change |
Corporate |
— |
| June 29, 2026 |
TENX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| June 29, 2026 |
IKT |
8-K filed: Leadership change |
Corporate |
— |
| June 29, 2026 |
UTHR |
8-K filed: Leadership change |
Corporate |
— |
| June 29, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 29, 2026 |
ALMS |
8-K filed: Other event |
Filing |
— |
| June 29, 2026 |
OTLC |
8-K filed: Material agreement |
Corporate |
— |
| June 29, 2026 |
LRMR |
8-K filed: Other event |
Filing |
— |
| June 29, 2026 |
NGNE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 29, 2026 |
BCRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 29, 2026 |
BYSI |
8-K/A filed: Leadership change |
Corporate |
— |
| June 30, 2026 |
GSK |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| June 30, 2026 |
SVA |
Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine |
Trial Milestone |
Phase 1 |
| June 30, 2026 |
AAPG |
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment |
Trial Milestone |
Phase 1 |
| June 30, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| June 30, 2026 |
NUVB |
8-K filed: Material agreement, Other event |
Corporate |
— |
| June 30, 2026 |
ZBIO |
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) |
Trial Milestone |
Phase 3 |
| June 30, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| June 30, 2026 |
PVLA |
8-K filed: Leadership change |
Corporate |
— |
| June 30, 2026 |
VTGN |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 30, 2026 |
TRVI |
NAL ER IPF Respiratory Function and Safety Study |
Trial Milestone |
Phase 1 |
| June 30, 2026 |
TENX |
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF |
Trial Milestone |
Phase 3 |
| June 30, 2026 |
TENX |
8-K filed: Material agreement |
Corporate |
— |
| June 30, 2026 |
ALXO |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| June 30, 2026 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 30, 2026 |
IMNN |
8-K filed: Leadership change |
Corporate |
— |
| June 30, 2026 |
STOK |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 30, 2026 |
PCRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| June 30, 2026 |
ORMP |
8-K filed: Other event |
Filing |
— |
| June 30, 2026 |
PVCT |
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment |
Trial Milestone |
Phase 4 |
| June 30, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| June 30, 2026 |
IRON |
8-K filed: Material agreement |
Corporate |
— |
| June 30, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| June 30, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| June 30, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 30, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| June 30, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| June 30, 2026 |
AKBA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| June 30, 2026 |
CLLS |
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) |
Trial Milestone |
Phase 1/Phase 2 |